Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Netupitant/palonosetron - Helsinn

Next Previous
Drug Profile

Netupitant/palonosetron - Helsinn

Alternative Names: AKYNZEO; Akynzeo; Fosnetupitant/palonosetron; NEPA - Helsinn; NEPA-IV; Palonosetron/Fosnetupitant; Palonosetron/netupitant

Latest Information Update: 20 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Helsinn
  • Developer CSL Vifor; Glenmark Pharmaceuticals Ltd; Helsinn; HK inno.N; Knight Therapeutics; Mundipharma International; Taiho Pharmaceutical
  • Class Antiemetics; Isoquinolines; Pyridines; Quinuclidines; Small molecules
  • Mechanism of Action Neurokinin 1 antagonists; Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting

Most Recent Events

  • 06 Aug 2026 Launched for Chemotherapy-induced nausea and vomiting (Prevention) in Paraguay prior to August 2026
  • 18 Feb 2026 Helsinn plans to launch fosnetupitant/palonosetron for Chemotherapy induced nausea and vomiting (Prevention) in the European Union, Iceland, Liechtenstein, Norway (PO, Suspension) in 2026
  • 12 Feb 2026 Registered for Chemotherapy-induced nausea and vomiting (Prevention) in Iceland, Liechtenstein, Norway, European Union (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top